Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Abdominal Cancer × Tadalafil × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 5 Prostatic Neoplasms 4 Head and Neck Neoplasms 3 Erectile Dysfunction 3 Pancreatic Neoplasms 2 Neoplasms 2 Carcinoma 2 Adenocarcinoma 2 Sexual Dysfunction, Physiological 1 Pyridoxine-dependent epilepsy 1 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neurotoxicity Syndromes 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Mouth Neoplasms 1 Liver Neoplasms 1 Glioblastoma 1 Gastric Adenocarcinoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Astrocytoma 1 Abdominal Cancer 1

Interventions

Bupivacaine 2 Tea 1 Tadalafil 1 Supine Position 1 Morphine 1 Lidocaine 1 Ketamine 1 Injections, Subcutaneous 1 Influenza Vaccines 1 Head-Down Tilt 1 Ethanol 1 Dexmedetomidine 1 Anesthetics, Local 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02998736 2022-12-28

PERIOP-04

Ottawa Hospital Research Institute

Phase 1 Completed

Abdominal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡